THOMAS J WALSH
Social Work at Battery Ln, Bethesda, MD
License number
Maryland 7000
Category
Social Work
Type
Clinical
Address
Address
4848 Battery Ln STE 202, Bethesda, MD 20814
Phone
(301) 656-6420
(301) 881-8733 (Fax)
(301) 881-8733 (Fax)
Organization information
See more information about THOMAS J WALSH at bizstanding.comTHOMAS J WALSH INSURANCE
5914 Kirby Rd, Bethesda, MD 20817
Industry:
Insurance Companies
Phone:
(301) 320-6166 (Phone)
Professional information
Thomas J Walsh, Bethesda MD
Specialties:
Social Work, Clinical Social Work
Address:
4848 Battery Ln STE 202, Bethesda 20814
(301) 656-6420 (Phone), (301) 881-8733 (Fax)
(301) 656-6420 (Phone), (301) 881-8733 (Fax)
Languages:
English
Adrenomedullin Peptides
US Patent:
6320022, Nov 20, 2001
Filed:
Feb 17, 1998
Appl. No.:
9/011922
Inventors:
Frank Cutitta - Adamstown MD
Alfredo Martinez - Washington DC
Mae Jean Miller - Monrovia MD
Edward J. Unsworth - Kensington MD
William Hook - Wheaton MD
Thomas Walsh - Bethesda MD
Karen Gray - Gaithersburg MD
Charles Macri - Kensington MD
Alfredo Martinez - Washington DC
Mae Jean Miller - Monrovia MD
Edward J. Unsworth - Kensington MD
William Hook - Wheaton MD
Thomas Walsh - Bethesda MD
Karen Gray - Gaithersburg MD
Charles Macri - Kensington MD
Assignee:
The United States of America as represented by the Department of Health and
Human Services - Washington DC
Human Services - Washington DC
International Classification:
A61K 3800, A61K 3804
US Classification:
530300
Abstract:
The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
Functional Role Of Adrenomedullin (Am) And The Gene Related Product (Pamp) In Human Pathology And Physiology
US Patent:
2010002, Jan 28, 2010
Filed:
Sep 29, 2009
Appl. No.:
12/569821
Inventors:
Frank Cuttitta - Adamstown MD, US
Alfredo Martinez - McLean VA, US
Mae Jean Miller - Monrovia MD, US
Edward J. Unsworth - Kensington MD, US
William A. Hook - Wheaton MD, US
Thomas Walsh - Bethesda MD, US
Karen Gray - Gaithersburg MD, US
Charles Macri - Kensington MD, US
Alfredo Martinez - McLean VA, US
Mae Jean Miller - Monrovia MD, US
Edward J. Unsworth - Kensington MD, US
William A. Hook - Wheaton MD, US
Thomas Walsh - Bethesda MD, US
Karen Gray - Gaithersburg MD, US
Charles Macri - Kensington MD, US
International Classification:
A61K 39/395, C07K 16/00, G01N 33/53, A61P 7/12, A61P 37/00
US Classification:
4241391, 5303879, 435 71
Abstract:
The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have show that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was show by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
Functional Role Of Adrenomedullin (Am) And The Gene-Related Product (Pamp) In Human Pathology And Physiology
US Patent:
7101548, Sep 5, 2006
Filed:
Aug 16, 2001
Appl. No.:
09/931700
Inventors:
Frank Cuttitta - Adamstown MD, US
Alfredo Martinez - McLean VA, US
Mae Jean Miller - Monrovia MD, US
Edward J. Unsworth - Kensington MD, US
William Hook - Wheaton MD, US
Thomas Walsh - Bethesda MD, US
Karen Gray - Gaithersburg MD, US
Charles Macri - Kensington MD, US
Alfredo Martinez - McLean VA, US
Mae Jean Miller - Monrovia MD, US
Edward J. Unsworth - Kensington MD, US
William Hook - Wheaton MD, US
Thomas Walsh - Bethesda MD, US
Karen Gray - Gaithersburg MD, US
Charles Macri - Kensington MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 39/395
US Classification:
4241301, 435 4, 435 71, 4241381, 4241391, 4241521
Abstract:
The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
Functional Role Of Adrenomedullin (Am) And The Gene-Related Product (Pamp) In Human Pathology And Physiology
US Patent:
2007000, Jan 4, 2007
Filed:
Sep 5, 2006
Appl. No.:
11/517599
Inventors:
Frank Cuttitta - Adamstown MD, US
Alfredo Martinez - McLean VA, US
Mae Miller - Monrovia MD, US
Edward Unsworth - Kensington MD, US
William Hook - Wheaton MD, US
Thomas Walsh - Bethesda MD, US
Karen Gray - Gaithersburg MD, US
Charles Macri - Kensington MD, US
Alfredo Martinez - McLean VA, US
Mae Miller - Monrovia MD, US
Edward Unsworth - Kensington MD, US
William Hook - Wheaton MD, US
Thomas Walsh - Bethesda MD, US
Karen Gray - Gaithersburg MD, US
Charles Macri - Kensington MD, US
International Classification:
A61K 39/395, A61K 38/22
US Classification:
514012000, 424145100
Abstract:
The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have show that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was show by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
Liposomal Nystatin Treatment Of Fungal Infection
US Patent:
2002012, Sep 12, 2002
Filed:
Sep 11, 2001
Appl. No.:
09/950980
Inventors:
Thomas Walsh - Bethesda MD, US
Assignee:
Aronex Pharmaceuticals, Inc.
International Classification:
A61K031/7048, A61K009/127
US Classification:
424/450000, 514/028000
Abstract:
A method of treating a urinary tract fungal infection in a human comprising systemically administering a therapeutically effective amount of a liposomal polyene including nystatin and amphotericin wherein the fungal infection is selected from the group consisting of aspergillosis, candidiasis (e.g., ), zygomycosis, cryptococcosis, histoplasmosis, blastomycosis, cladosporiosis, fusariosis, , torulopsosis, , and